Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:MTSRNASDAQ:VKTXNYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$65.62+8.4%$62.70$47.86▼$107.37$3.62B0.34593,919 shs1.92 million shsMTSRMetsera$28.53-2.5%$23.03$12.30▼$32.81$3.00BN/A882,225 shs790,422 shsVKTXViking Therapeutics$27.27-4.9%$26.09$18.92▼$81.73$3.06B0.754.08 million shs1.98 million shsZYMEZymeworks$11.93-4.0%$11.80$8.21▼$17.70$830.19M1.24599,277 shs267,133 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+3.47%+3.93%-2.39%-4.35%+11.37%MTSRMetsera+1.00%+12.07%+49.46%-8.34%+2,924,999,900.00%VKTXViking Therapeutics+4.25%+3.35%+19.76%-11.21%-57.54%ZYMEZymeworks+5.16%+7.06%+7.81%-16.13%+38.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.8507 of 5 stars3.50.00.00.03.42.50.0MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/AVKTXViking Therapeutics4.4315 of 5 stars4.51.00.04.73.03.30.0ZYMEZymeworks3.5572 of 5 stars4.50.00.00.04.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.3369.68% UpsideMTSRMetsera 3.00Buy$47.0064.74% UpsideVKTXViking Therapeutics 3.00Buy$87.15219.57% UpsideZYMEZymeworks 2.90Moderate Buy$21.0076.00% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, ACLX, MTSR, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.003/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.00(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$76.81M47.08N/AN/A$9.97 per share6.58MTSRMetseraN/AN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/AZYMEZymeworks$93.38M8.89N/AN/A$6.63 per share1.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.99N/AN/AN/A-25.94%-8.28%-5.21%N/AMTSRMetseraN/AN/A0.00∞N/AN/AN/AN/AN/AVKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%8/7/2025 (Estimated)Latest ZYME, ACLX, MTSR, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/A2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29MTSRMetseraN/AN/AN/AVKTXViking TherapeuticsN/A36.4736.47ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%MTSRMetseraN/AVKTXViking Therapeutics76.03%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipACLXArcellx6.24%MTSRMetseraN/AVKTXViking Therapeutics4.10%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.11 million50.70 millionOptionableMTSRMetsera81105.06 millionN/AN/AVKTXViking Therapeutics20112.31 million106.20 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableZYME, ACLX, MTSR, and VKTX HeadlinesRecent News About These CompaniesZymeworks Inc. Presents Promising Preclinical Data for ZW1528, a Novel Bispecific Antibody Targeting IL-4Rα and IL-33 for Respiratory InflammationMay 21 at 4:05 PM | nasdaq.comZymeworks Inc. (NYSE:ZYME) Stake Lessened by Vestal Point Capital LPMay 21 at 8:14 AM | marketbeat.comTD Securities Initiates Coverage of Zymeworks (ZYME) with Buy RecommendationMay 21 at 6:48 AM | msn.comTD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer TherapyMay 21 at 6:48 AM | msn.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 21 at 6:00 AM | globenewswire.comZymeworks Inc.: Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International ConferenceMay 20 at 10:43 AM | finanznachrichten.dePolar Asset Management Partners Inc. Buys New Holdings in Zymeworks Inc. (NYSE:ZYME)May 20 at 5:29 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 5,919 SharesMay 20 at 5:17 AM | insidertrades.comZymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International ConferenceMay 19 at 4:15 PM | globenewswire.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Prosight Management LPMay 17, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $5.21 Million Position in Zymeworks Inc. (NYSE:ZYME)May 17, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Buys Shares of 22,800 Zymeworks Inc. (NYSE:ZYME)May 15, 2025 | marketbeat.comWall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a BetMay 14, 2025 | zacks.comAnalyst Forecasts For Zymeworks Inc. (NASDAQ:ZYME) Are Surging HigherMay 14, 2025 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Granahan Investment Management LLCMay 12, 2025 | marketbeat.comFarallon Capital Management LLC Sells 31,026 Shares of Zymeworks Inc. (NYSE:ZYME)May 11, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases 123,240 Shares of Zymeworks Inc. (NYSE:ZYME)May 11, 2025 | marketbeat.comZymeworks May 2025 slides: Pipeline expansion amid modest revenue growthMay 10, 2025 | investing.comZymeworks Inc. Reports Financial Results and Highlights Recent Developments, Including Appointment of Dr. Sabeen Mekan and AACR Poster PresentationsMay 10, 2025 | nasdaq.comZymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comZymeworks Inc. (NYSE:ZYME) Shares Bought by Voya Investment Management LLCMay 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Viking Therapeutics Stock May Struggle After As-Expected ReportBy Chris Markoch | April 25, 2025View Viking Therapeutics Stock May Struggle After As-Expected ReportZYME, ACLX, MTSR, and VKTX Company DescriptionsArcellx NASDAQ:ACLX$65.61 +5.08 (+8.38%) Closing price 03:59 PM EasternExtended Trading$65.48 -0.13 (-0.20%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Metsera NASDAQ:MTSR$28.53 -0.72 (-2.46%) As of 03:51 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Viking Therapeutics NASDAQ:VKTX$27.27 -1.40 (-4.88%) Closing price 03:59 PM EasternExtended Trading$27.34 +0.07 (+0.25%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Zymeworks NYSE:ZYME$11.93 -0.50 (-4.01%) Closing price 03:59 PM EasternExtended Trading$11.94 +0.01 (+0.07%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks: Buy The Dip, Long-Term Tailwinds Ahead Lowe’s Stock Uptrend Can Continue for These 2 Reasons CrowdStrike Near Breakout: Is Now the Time to Buy? Rivian Stock Below $20: Charging Up or in the Breakdown Lane? Viking Holdings Posts Strong Q1, Eyes Growth Ahead 2 Reasons Netflix’s 40% Rally Is Far From Over Qualcomm’s Re-Entry Into the CPU Market May Not Be Enough Applied Digital's Strategic AI Play Gains Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
